Cargando…
Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome
BACKGROUND: Ticagrelor has a Class I recommendation for use following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS). However, ticagrelor needs to be taken twice a day, as compared to clopidogrel. Its adverse effects, such as dyspnea or bleeding, are known to be more commo...
Autores principales: | Moon, Hyeyeon, Jo, Yoon-Sung, Kim, Soo-Jin, Jo, Sua, Park, Kyungil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520288/ https://www.ncbi.nlm.nih.gov/pubmed/34656119 http://dx.doi.org/10.1186/s12955-021-01875-w |
Ejemplares similares
-
Different Microcirculation Response Between Culprit and Non‐Culprit Vessels in Patients With Acute Coronary Syndrome
por: Jo, Yoon‐Sung, et al.
Publicado: (2020) -
Design and Rationale for comParison Between ticagreLor and clopidogrEl on mIcrocirculation in Patients with Acute cOronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO) Trial
por: Park, Kyungil, et al.
Publicado: (2018) -
Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2023) -
Ticagrelor Versus Clopidogrel in East Asian Patients With Acute Coronary Syndrome and Diabetes Mellitus
por: Choi, Yeonwoo, et al.
Publicado: (2022) -
Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel
por: ALGÜL, Engin, et al.
Publicado: (2019)